# Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

> **NCT00165464** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 54 (actual)

## Conditions studied

- Esophageal Cancer
- Gastric Cancer
- GE Junction Cancer

## Interventions

- **DRUG:** Taxotere
- **DRUG:** Cisplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00165464
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-08
- **Primary completion:** 2005-03
- **Final completion:** 2009-04
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2009-04-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00165464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00165464, "Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00165464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*